News

Visbiome® is a high potency probiotic medical food designed to manage microbial imbalances associated with medical conditions such as irritable bowel syndrome (IBS), Ulcerative Colitis (UC), Antibiotic-Associated Diarrhea (AAD), Pouchitis, and Hepatic Encephalopathy (HE). With a proven track record in over 80 human clinical trials performed over the past 20 years, Visbiome® is the most extensively researched multi-strain probiotic available.

April 5, 2023 – ExeGi Pharma, LLC, owner of the Visbiome probiotic, has secured a significant legal victory against Brookfield Pharmaceuticals, LLC...

Novel study evaluates the microbiota-gut-brain axis as a pathway to supportive care in mental health challenges June 8, 2022 (Rockville, MD) – A n...

ExeGi Pharma LLC, the makers of Visbiome, announced today that the United State Court of Appeals for the Fourth Circuit has upheld a prior $15 million jury verdict in which the sellers of the VSL#3® probiotic were found liable for false advertising.

  October 15, 2020 (Rockville, Maryland) – A new study published in the peer-reviewed journal Frontiers in Psychiatry finds the high-potency De Sim...

November 12, 2020 (Rockville, Maryland): ExeGi Pharma LLC, a company focused on developing live biotherapeutic ("LBP") drugs and probiotics, announ...

The Visbiome team is excited to announce new sustainable packaging for Visbiome Capsules, which will start shipping in the coming weeks. ExeGi Pha...

COVID-19 continues to cause nationwide shutdowns and quarantines, and the timeline regarding a return to normalcy remains uncertain. Because even o...

Over the past few weeks, it’s become clear that the world is facing an unprecedented challenge. As the Coronavirus (COVID-19) continues to affect o...

Visbiome subscriptions allow customers to set up automatic shipments, ensuring that they never have to worry about their order.